Table 1.

P-Values for Endpoint Nasal Congestion Relief for ASA/PSE-Comparisons

Outcome	Comparison	0–1 hours	0–2 hours	0–3 hours	0–4 hours	Day 3
Airflow conductance area under the curve (AUC)	ASA/PSE versus ASA	<0.001	<0.001	<0.001	<0.001b	n.a
	ASA/PSE versus PSE	0.585	0.592	0.798	0.933	n.a.
	ASA/PSE versus Placebo	<0.001	<0.001	<0.001	<0.001	n.a.
Sum of subjective nasal congestion intensity differences (SNCID)a	ASA/PSE versus ASA	n.a	n.a	n.a.	0.144	0.969
	ASA/PSE versus PSE	n.a.	n.a.	n.a	0.647	0.371
	ASA/PSE versus Placebo	n.a.	n.a.	n.a.	0.008	0.048
Total subjective nasal congestion relief (TCNR)a	ASA/PSE versus ASA	n.a.	n.a.	n.a.	<0.001	0.016
	ASA/PSE versus PSE	n.a	n.a	n.a	0.890	0.873
	ASA/PSE versus Placebo	n.a.	n.a.	n.a.	<0.001	<0.001
Global nasal congestion relief	ASA/PSE versus ASA	n.a	n.a	n.a.	n.a.	0.040
	ASA/PSE versus PSE	n.a.	n.a.	n.a.	n.a.	0.207
	ASA/PSE versus Placebo	n.a.	n.a.	n.a.	n.a.	<0.001

n.a., not applicable.

^aMann–Whitney U-test.

^bPrimary endpoint.